James N. Kochenderfer, M.D.
Dr. Kochenderfer is a physician-scientist working to develop immunotherapies for lymphoma, leukemia, and multiple myeloma. His current work focuses on chimeric antigen receptor T-cell therapies. Chimeric antigen receptors (CARs) are fusion proteins that recognize malignant cells. T cells genetically engineered to express CARs can be infused into patients to treat cancer. Dr. Kochenderfer leads laboratory studies of CAR T-cell biology and clinical studies of CAR T-cell therapies for multiple myeloma and for treatment of B-cell malignancies after allogeneic hematopoietic stem cell transplantation.
Dr. Kochenderfer's research is aimed at developing T-cell therapies for hematogic malignancies. T cells normally play a critical role in fighting infections. Under certain circumstances, T cells can exert a powerful and specifically-targeted anti-malignancy effect. Dr. Kochenderfer's current laboratory work involves genetic engineering of T cells with genes encoding chimeric antigen receptors that target malignancy-associated antigens. This work has led to two clinical trials in which patients receive infusions of T cells that are genetically engineered to specifically recognize and eliminate cells expressing the CD19 antigen, which is expressed by most B-cell lymphomas and B-cell leukemias. These clinical trials have produced the first evidence that genetically-engineered T cells can eliminate CD19-expressing cells in humans.
Selected Recent Publications
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.J Clin Oncol. 35: 1803-1813, 2017. [ Journal Article ]
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.Blood. 128 1688-700: 2016. [ Journal Article ]
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.J Clin Oncol. 34: 1112-21, 2016. [ Journal Article ]
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.J Clin Oncol. 36/22: 2267-2280, 2018. [ Journal Article ]
Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.Mol Ther. 25/11: 2452-2465, 2017. [ Journal Article ]
Dr. Kochenderfer is a clinician and translational researcher in the Experimental Transplantation and Immunology Branch of the National Cancer Institute (NCI). Dr. Kochenderfer conducts research aimed at developing new T-cell therapies for lymphoma and leukemia. His clinical expertise lies in the areas of hematopoietic stem cell transplantation and hematologic malignancies. Dr. Kochenderfer received his M.D. from West Virginia University in 1995, and he completed clinical training in internal medicine at Vanderbilt University. He completed oncology and hematology fellowships at the University of Texas M.D. Anderson Cancer Center and at Baylor College of Medicine. He completed further training in tumor immunology and stem cell transplantation at the NCI prior to assuming his current position as an Assistant Clinical Investigator.
|Christina Amatya Ph.D.||Postdoctoral Fellow (Visiting)|
|Jennifer Brudno M.D.||Staff Clinician|
|Ashley Carpenter R.N.||Research Nurse|
|Stephanie Choi B.S.||Postbaccalaureate Fellow (CRTA)|
|Michaela Ganaden R.N.||Research Nurse|
|Brenna Hansen R.N.||Research Nurse|
|Norris Lam B.S.||Biologist|
|Jennifer Mann||Nurse Practitioner|
|Lekha Mikkilineni M.D.||Medical Oncology Clinical Fellow|
|Rachael Mohn B.S.||Patient Care Coordinator (Contr.)|
|Danielle Vanasse B.S.||Research Technician (Contr.)|
|Shicheng Yang Ph.D.||Principal Scientist, Leidos Biomedical Research, Inc.|